Risedronate sodium 75 MG Oral Tablet [Actonel] — RxCUI 905086
RxNorm drug concept · Semantic branded drug
RxCUI 905086
Semantic branded drug · SBD
Retired or remapped concept 2 FDA products
2 package NDCs
Snapshot Jul 14, 2026
What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.
🗂️ Key Facts
RxCUI905086
Official nameRisedronate sodium 75 MG Oral Tablet [Actonel]
Concept typeSemantic branded drug (SBD)
RxNorm statusRetired or remapped concept
FDA products mapped2
Package NDCs mapped2
RxNorm release07/06/2026
Snapshot dataJul 14, 2026
📖 Skip the Codes — Read It in Plain English.
Our pharmacist-built guide to Risedronate: what it is, how it’s used, side effects, and interactions.
📗 Our plain-language guide HelloPharmacist
- It helps strengthen bones. Depending on the product, it treats or prevents osteoporosis in postmenopausal women, treats osteoporosis in men, treats or prevents steroid-related oste...
- Regular tablets go down whole with a full glass of plain water at least 30 minutes before food, drink or other medicines. Delayed-release tablets are taken right after breakfast wi...
- Back pain, joint pain, belly pain and indigestion are the most common. Call your doctor if you have painful swallowing, chest pain, new heartburn, severe bone or muscle pain, or ne...
- Not at the same time. Calcium, antacids, magnesium products and iron can block absorption, so take them at a different time of day. Do get enough calcium and vitamin D, as your doc...
🕸️ Concept Web
No related-concept groups were available for this RxCUI in the loaded RxNorm data. That does not prove that no related concepts exist.
📦 FDA Products & Package NDCs
2 products · 2 package NDCs
2 package NDCs map to RxCUI 905086 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
| Package NDC | Package | Brand / generic name | Labeler | Marketing start |
|---|---|---|---|---|
| 00430-0472-03 | 4 TABLET, FILM COATED in 1 DOSE PACK (0430-0472-03) | Actonel | Allergan, Inc. | 2002-05-17 |
| 00430-0478-01 | 1 TABLET, FILM COATED in 1 DOSE PACK (0430-0478-01) | Actonel | Allergan, Inc. | 2008-04-22 |
Observed labelers:
Allergan, Inc. (2)
— this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.
🗃️ Sources & Limits
Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
- A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
- Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
- Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
- Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.
Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.